about
Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer.Q28085663Interrater reliability in interpretation of electrocorticographic seizure detections of the responsive neurostimulator.Concordance in diabetic foot ulcer infectionPressure RElieving Support SUrfaces: a Randomised Evaluation 2 (PRESSURE 2) photographic validation sub-study: study protocol for a randomised controlled trial.IMPROVDENT: improving dentures for patient benefit. A crossover randomised clinical trial comparing impression materials for complete denturesThe TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisThe 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugThe MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary reEffect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.Pressure RElieving Support SUrfaces: a Randomised Evaluation 2 (PRESSURE 2): study protocol for a randomised controlled trial.Exploring the role of pain as an early predictor of category 2 pressure ulcers: a prospective cohort study.The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome.Clinical Evaluation of a New Pressure Ulcer Risk Assessment Instrument, the Pressure Ulcer Risk Primary or Secondary Evaluation Tool (PURPOSE T).The cost-effectiveness of tight control of inflammation in early psoriatic arthritis: Economic analysis of the TICOPA trial.Concordance in diabetic foot ulceration: a cross-sectional study of agreement between wound swabbing and tissue sampling in infected ulcers.Pressure ulcer and wounds reporting in NHS hospitals in England part 1: Audit of monitoring systems.Pressure ulcer and wounds reporting in NHS hospitals in England part 2: Survey of monitoring systems.A Disease-Specific Hybrid Rotation Increases Opportunities for Deliberate Practice.CODIFI (Concordance in Diabetic Foot Infection): Agreement in reported presence of likely pathogens in swabs and tissue samples from infected diabetic foot ulcers.Assessing the accuracy of routinely collected data and their potential use in pressure ulcer trials.Using results from a UK-wide survey to justify choice of comparator for the treatment of severe chronic hand eczema.Pressure relieving support surfaces: a randomised evaluation 2 (PRESSURE 2).Association of Tumor HER3 Messenger RNA Expression With Panitumumab Efficacy in Advanced Colorectal Cancer.A Flexible Postoperative Debriefing Process Can Effectively Provide Formative Resident Feedback
P50
Q27853335-7089FAE3-6102-4EA7-B1C0-76B6EB5998DAQ28085663-8CA23A1B-D800-4D90-A675-DC1615AF9E6AQ30300157-542C34A8-6BF4-4645-B38D-B5C1C3BF51DFQ30532685-824ACEB5-CA2C-4AA9-B9D1-1AFA02A2520CQ30842501-2976111C-9D88-4E6C-BEB1-D675C45243B0Q34399992-B78ED64D-A0AE-401D-B9BC-36F61647337FQ34630959-A667B58A-2B8B-443E-9E4E-D30005E3297CQ35336802-6DA9E4FC-2FD7-4A4C-83E0-225B692AD002Q36020680-726A5DA8-D4DF-4B9B-9F38-74DDEDD58471Q37036355-E42525E7-9091-43F1-ABAA-F826047CAEFAQ37517495-7D31E78E-F6E5-4C95-B192-2499C3FAC964Q37598296-F85B650F-5DA0-49F9-BFF0-736AE5938977Q37607603-D58A846E-6274-4FB2-A9E4-499712AAF917Q38612195-E25D1F73-A049-477A-BE5D-C90A00847C83Q38678945-C5F6BCB1-25BD-4031-9284-CC1DCFE194A6Q38797187-001AD601-BD5B-4CE3-A65F-59D42A6CFF50Q40096434-15109F66-1148-42FC-8C40-64E417867F0BQ40100021-5326F407-0457-48F2-B68E-3170D6C5C17DQ40415850-51893497-6092-4D50-B1D7-AE46A812E746Q45906873-4CA7A27A-32EE-4956-B653-0BAC5DB3FB42Q45956469-BC94F26C-8358-42DE-80F0-98DC921DEC30Q45983113-92E8AE5F-9164-4AB3-ADBC-BBA35ED34BD7Q46426980-7069E19B-D3F5-409D-8041-BA424D0FC380Q47707557-11C20667-C973-4B20-8D44-67FB54AD1EE1Q58417115-3CFA84E2-04F5-426D-A5EE-14C42A536F5E
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Sarah Brown
@ast
Sarah Brown
@cy
Sarah Brown
@en
Sarah Brown
@en-gb
Sarah Brown
@es
Sarah Brown
@nl
Sarah Brown
@sl
type
label
Sarah Brown
@ast
Sarah Brown
@cy
Sarah Brown
@en
Sarah Brown
@en-gb
Sarah Brown
@es
Sarah Brown
@nl
Sarah Brown
@sl
prefLabel
Sarah Brown
@ast
Sarah Brown
@cy
Sarah Brown
@en
Sarah Brown
@en-gb
Sarah Brown
@es
Sarah Brown
@nl
Sarah Brown
@sl
P1053
D-9335-2016
P106
P1153
11638968900
56604496800
P2031
1998-01-01T00:00:00Z
P21
P31
P3829
P496
0000-0002-4438-9869